Article
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.
Breast cancer research : BCR - 20 Jul 2012
Byrski Tomasz, Dent Rebecca, Blecharz Pawel, Foszczynska-Kloda Malgorzata, Gronwald Jacek, Huzarski Tomasz, Cybulski Cezary, Marczyk Elzbieta, Chrzan Robert, Eisen Andrea, Lubinski Jan, Narod Steven A
Abstract excerpt
INTRODUCTION: The purpose of this investigation was to evaluate the efficacy of cisplatin chemotherapy in BRCA1 mutation carriers with metastatic breast cancer. METHODS: In a phase II, open-label study, 20 patients with metastatic breast cancer who carried a mutation in BRCA1 were treated with cisplatin 75 mg/m2 intravenously every 3 weeks as part of a 21-day cycle for 6 cycles. Restaging studies to assess...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.